ClinicalTrials.gg
CompletedNCT01734382Updated Apr 24, 2020Results posted

A Study of Decreased Dose Frequency in Participants With Systemic Juvenile Arthritis Who Experience Laboratory Abnormalities During Treatment With RoActemra/Actemra (Tocilizumab)

A Phase 4 interventional study of Tocilizumab in Juvenile Idiopathic Arthritis, sponsored by Hoffmann-La Roche. Completed at 19 sites in 10 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2020-04-24.

Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
35
Allocation
Non-randomized
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies testing tocilizumab in Arthritis, Juvenile — 2 open to participants now, 2 under way, 1 of them phase 3. tocilizumab · Arthritis, Juvenile.

Enrollment
13th of 21
35 · median 52
Started
2013
with 4 others
Phase 4
2 of 21
none open now
Registered
14th of 21
by date
Lead sponsor
12 of 21
Hoffmann-La Roche

Among the 21 studies testing tocilizumab in Arthritis, Juvenile, this one is the 13th largest by enrollment, is one of 5 that started in 2013, is one of 2 in phase 4, and was the 14th registered.

Arthritis, Juvenile

366 studies on the registry are indexed under Arthritis, Juvenile; 101 are open to participants now.

Browse Arthritis, Juvenile studies →

Open to participants now

2 of the 21 studies testing tocilizumab in Arthritis, Juvenile are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About tocilizumab

tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 69 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 50 (72%) stop at 75 or younger; 65 take children under 18; 11 take healthy volunteers.

This study: 2 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing tocilizumab in Arthritis, Juvenile, or all of them as a file.
02

Study summary

PART1 Participants in Part 1 (Run-in-Phase) of study will receive tocilizumab (TCZ) (RoActemra/Actemra) 12 milligrams per kilogram (mg/kg) or 8 mg/kg intravenously (IV) every 2 weeks (Q2W) for up to 24 weeks. Participants who experience a laboratory abnormality during Part 1 may be eligible to move into Part 2 of the study.

PART 2 This open-label Phase IV study will evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics and immunogenicity of tocilizumab in reduced dose frequency in participants with adequately controlled systemic juvenile idiopathic arthritis who have experienced a laboratory abnormality on twice weekly tocilizumab dosing, that has since resolved. Participants will receive tocilizumab 12 mg/kg or 8 mg/kg intravenously every 3 weeks. After 5 consecutive infusions, participants who experience an event of neutropenia, thrombocytopenia or liver enzyme abnormality will move to every 4 weeks tocilizumab administration. Anticipated time on study treatment is 52 weeks.

03

Conditions studied

  • Juvenile Idiopathic Arthritis

Browse trials for

04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

PART 1 and 2

  • Children 2 to 17 years of age inclusive at screening
  • Systemic juvenile idiopathic arthritis (sJIA) according to International League of Associations for Rheumatology (ILAR) classification (2001) and sJIA symptoms lasting for at least 1 month since diagnosis of sJIA
  • Must meet one of the following:
  • Not receiving methotrexate (MTX) or discontinued MTX at least 4 weeks prior to baseline visit, or
  • Taking MTX for at least 12 weeks immediately prior to the baseline visit and on a stable dose of less than or equals (\</=) 20 milligrams per meter square (mg/m\^2) for at least 8 weeks prior to the baseline visit, together with either folic acid or folinic acid according to local standard of care
  • Participants entering Part 1 who are naive to TCZ therapy must also meet the following inclusion criterion:
  • History of inadequate clinical response (in the opinion of the treating physician) to Non steroidal Anti-Inflammatory Drugs (NSAIDs) and PART 2
  • Juvenile Arthritis Disease Activity Score (JADAS) -71 score of 3.8 or less and absence of fever (related to sJIA) at screening and baseline
  • Neutropenia, thrombocytopenia, or elevated /Aspartate transaminase (ALT/AST) previously experienced on the labeled dose (Q2W) of RoActemra/Actemra at any time
  • Not currently receiving oral corticosteroids, or taking oral corticosteroids at a stable dose for a minimum of 2 weeks prior to baseline visit at no more than 10 milligrams per day (mg/day) or 0.2 miiligrams per kilogram per day (mg/kg/day), whichever is less
  • Not taking (NSAIDs), or taking no more than 1 type of NSAID at a stable dose for a minimum of 2 weeks prior to the baseline visit, with the dose being less than or equal to the maximum recommended daily dose

Exclusion criteria

Exclusion Criteria:

  • Wheelchair bound or bedridden
  • Any other auto-immune, rheumatic disease, or overlap syndrome other than sJIA
  • Pregnant or lactating, or intending to become pregnant during study conduct and up to 6 months after the last administration of study drug
  • Any significant concurrent medical or surgical condition which would jeopardize the participant's safety or ability to complete the trial
  • History of significant allergic or infusion reactions to prior TCZ infusion, and/or presence of anti-TCZ antibodies at screening
  • Inborn conditions characterized by a compromised immune system
  • Known (HIV) infection or other acquired forms of immune compromise
  • History of alcohol, drug, or chemical abuse within 6 months of screening
  • Evidence of serious uncontrolled concomitant diseases, including but not limited to the nervous, renal, hepatic, or endocrine systems
  • Any active acute, subacute, chronic or recurrent bacterial, viral, or systemic fungal infection
  • History of atypical tuberculosis (TB)
  • Active TB requiring treatment within 2 years prior to the screening visit
  • Positive purified protein derivative (PPD) at screening
  • Any major episode of infection requiring hospitalization or treatment during screening or treatment with IV antibiotics completing within 4 weeks of the screening visit or oral antibiotics completing within 2 weeks of the screening visit
  • History of reactivation or new onset of a systemic infection within 2 months of the screening visit
  • Positive for or infection
  • Chronic hepatitis, viral or pulmonary disease
  • Significant cardiac or pulmonary disease
  • History of or current cancer or lymphoma
  • Uncontrolled diabetes mellitus
  • History of or concurrent serious gastrointestinal disorders
  • History of macrophage activation syndrome (MAS) within 3 months prior to screening visit
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Part 1: Tocilizumab (TCZ) Q2W

    Participants will receive tocilizumab intravenous (IV) infusions (12 mg/kg for participants \< 30 kg; 8 mg/kg for participants \>/= 30 kg) once every other week (Q2W) up to 24 weeks or until occurrence of a protocol defined laboratory abnormality in Part 1 of the study.

    Drug: Tocilizumab

  • Experimental
    Part 2: TCZ IV 12 mg/kg Q3W/Q4W

    Participants with weight \< 30 kg will receive tocilizumab IV infusions of 12 mg/kg once every three weeks (Q3W) up to 52 weeks or until occurrence of neutropenia, thrombocytopenia, or liver enzyme abnormality as per protocol criteria. Participants who complete 5 consecutive infusions of Q3W and have a laboratory abnormality of neutropenia, thrombocytopenia or elevated liver enzymes as per protocol criteria, after resolution of this laboratory abnormality will switch to tocilizumab IV infusions of 12 mg/kg once every four weeks (Q4W) up to Week 52 in Part 2 of the study.

    Drug: Tocilizumab

  • Experimental
    Part 2: TCZ IV 8 mg/kg Q3W/Q4W

    Participants with weight \>/= 30 kg will receive tocilizumab IV infusions of 8 mg/kg Q3W up to 52 weeks or until occurrence of neutropenia, thrombocytopenia, or liver enzyme abnormality as per protocol criteria. Participants who complete 5 consecutive infusions of Q3W and have a laboratory abnormality of neutropenia, thrombocytopenia or elevated liver enzymes as per protocol criteria, after resolution of this laboratory abnormality will switch to tocilizumab IV infusions of 8 mg/kg Q4W up to Week 52 in Part 2 of the study.

    Drug: Tocilizumab

Interventions

  • Participants will receive tocilizumab IV infusions of 12 mg/kg (for participants \< 30 kg) or 8 mg/kg (for participants \>/=30 kg) Q2W/Q3W/Q4W.

    Also known as: RoActemra/Actemra

06

What researchers measure

Primary outcomes

  1. Juvenile Arthritis Disease Activity Score (JADAS-71)

    JADAS-71 has 4 components: Physician global assessment of disease activity on a visual analog scale (VAS) (range=0-10, left end of line=arthritis inactive, i.e., symptom-free and no arthritis symptoms; right end=arthritis very active), patient/parent global assessment of overall well-being on VAS (range=0-10, left end of line=very well, right end=very poor), normalized erythrocyte sedimentation rate (ESR) (range=0-10, If ESR is ≤20 mm/h, set to 0. If ≥120 mm/h, set to 10 mm/h. If \> 20 mm/h and \< 120 mm/h, apply formula: \[ESR-20 mm/h\]/10 mm/h), and a count of active arthritis (swelling present or pain present and limitation of motion) in 71 selected joints (range=0-71). JADAS-71 is sum of 4 component scores, range=0-101. A higher score=more arthritis disease activity. Data reported for up to Week 52 was collected in Part 2: Q3W arms: Baseline, Weeks 3,6,9,12,24,36,48 and 51; Q4W arms: Baseline, Weeks 0,4,8,12,24,36 and 40.

    Time frame: Part 2: Up to 52 weeks

  2. Number of Participants With Juvenile Idiopathic Arthritis (JIA) Disease Flare as Determined by JIA Core Variables in Part 2 of the Study

    JIA flare was defined as any 3 of the 6 core outcome variables worsening by at least 30% relative to baseline visit of Part 2, with no more than 1 of the remaining variables improving by more than 30%. For the number of joints with active arthritis or the number of joints with limitation of motion a minimum worsening of at least 2 joints had to be present. If the physician global assessment (PGA) or the parent/patient global assessment were used a minimum worsening of at least 2 units on a scale from 0 to 10 had be present. For erythrocyte sedimentation rate (ESR), a worsening of at least 30% was not considered if within normal ranges. The 6 core outcome variables: PGA of disease activity, parent/patient global assessment of overall well-being, number of joints with active arthritis, number of joints with limitation of movement, ESR (measure of acute phase reaction) and functional ability determined by Childhood Health Assessment Questionnaire (CHAQ) Disability Index.

    Time frame: Part 2: Up to 52 weeks

  3. Number of Participants With Fever Attributable to Systemic Juvenile Idiopathic Arthritis (sJIA) in Part 2 of the Study

    Absence of fever at screening visit was defined as a temperature measurement \< 38 degree centigrades (C). Presence of fever at each study visit was defined as a temperature measurement ≥ 38 C.

    Time frame: Part 2: Up to 52 weeks

Secondary outcomes

  1. Number of Participants With at Least One Adverse Event

    An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.

    Time frame: Part 1 - Baseline up to 24 weeks plus 12 weeks of safety follow up; Part 2 - Baseline up to 52 weeks plus 12 weeks of safety follow up

  2. Serum Interleukin-6 (IL-6) Protein Concentration in Part 2 of the Study

    Time frame: Part 2: Q3W arms: Pre-dose at Baseline, Weeks 3, 6, 9, 12, 24, 36, 48 and 51; Q4W arms: Pre-dose at Baseline, Weeks 0, 4, 8, 12, 24, 36 and 40

  3. Soluble IL-6 Receptor (sIL-6R) Protein Concentration in Part 2 of the Study

    Time frame: Part 2: Q3W arms: Pre-dose at Baseline, Weeks 3, 6, 9, 12, 24, 36, 48 and 51; Q4W arms: Pre-dose at Baseline, Weeks 0, 4, 8, 12, 24, 36 and 40

  4. C-reactive Protein (CRP) Concentration in Part 2 of the Study

    Time frame: Part 2: Q3W arms: Pre-dose at Baseline, Weeks 3, 6, 9, 12, 24, 36, 48 and 51; Q4W arms: Pre-dose at Baseline, Weeks 0, 4, 8, 12, 24, 36 and 40

  5. Erythrocyte Sedimentation Rate (ESR) in Part 2 of the Study

    Time frame: Part 2: Q3W arms: Pre-dose at Baseline, Weeks 3, 6, 9, 12, 24, 36, 48 and 51; Q4W arms: Pre-dose at Baseline, Weeks 0, 4, 8, 12, 24, 36 and 40

  6. Number of Participants With Anti-TCZ Antibodies in Part 2 of the Study

    Time frame: Part 2: Up to Week 52

  7. Serum TCZ Concentration in Part 2 of the Study

    Time frame: Part 2: Q3W arms: Pre-dose at Baseline, Weeks 3, 6, 9, 12, 24, 36, 48 and 51; Q4W arms: Pre-dose at Baseline, Weeks 0, 4, 8, 12, 24, 36 and 40

  8. Baseline Childhood Health Assessment Questionnaire (CHAQ) Disability Index in Part 2 of the Study

    CHAQ- Disability Index consists of 30 questions in 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities-distributed, among a total of 30 items. Each question was rated on 4-point scale with range 0=no difficulty to 3=unable to do. To calculate overall score, participant must have a domain score in at least 6 of 8 domains. Scores were averaged to calculate CHAQ disability index, range is 0=no/minimal physical dysfunction)-3=very severe physical dysfunction, higher score indicates more disability.

    Time frame: Baseline of Part 2

  9. Change From Baseline in Childhood Health Assessment Questionnaire (CHAQ) Disability Index in Part 2 of the Study

    CHAQ- Disability Index consists of 30 questions in 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities-distributed, among a total of 30 items. Each question was rated on 4-point scale with range 0=no difficulty to 3=unable to do. To calculate overall score, participant must have a domain score in at least 6 of 8 domains. Scores were averaged to calculate CHAQ disability index, range is 0=no/minimal physical dysfunction)-3=very severe physical dysfunction, higher score indicates more disability. Negative change from baseline indicates an improvement.

    Time frame: Baseline; Part 2: Q3W arm groups - Weeks 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48 and 51; Q4W arm groups - Weeks 0, 4, 8, 12, 16, 20, 24, 28, 32, 36 and 40

  10. Baseline Participant's/Parent's Global Assessment of Overall Well-being Score in Part 2 of the Study

    Participant's/parent's global assessment of overall well-being was determined on a VAS (range = 0-100, left end of the line = very well, i.e., symptom-free and no arthritis disease activity; right end = very poor, i.e., maximum arthritis disease activity).

    Time frame: Baseline of Part 2

  11. Change From Baseline in Participant's/Parent's Global Assessment of Overall Well-being Score in Part 2 of the Study

    Participant's/Parent's global assessment of overall well-being was determined on a VAS (range = 0-100, left end of the line = very well, i.e., symptom-free and no arthritis disease activity; right end = very poor, i.e., maximum arthritis disease activity). Reported is the change from baseline in VAS score with a negative change from baseline indicating an improvement.

    Time frame: Baseline; Part 2: Q3W arm groups - Weeks 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48 and 51; Q4W arm groups - Weeks 0, 4, 8, 12, 16, 20, 24, 28, 32, 36 and 40

07

Results

Posted Apr 24, 2020

Participant flow

Participants with systemic juvenile idiopathic arthritis (sJIA) were recruited at study sites in 8 countries. The study consisted of two parts: Part 1 was a 24-week Run-in period and Part 2 was a 52-week Main study.

Part 1
Participant flow — Part 1
MilestonePart 1: Tocilizumab (TCZ) Q2WPart 2: TCZ IV 12 mg/kg Q3W/Q4WPart 2: TCZ IV 8 mg/kg Q3W/Q4W
Started1900
Completed1700
Not completed200
Withdrew: Adverse event200
Part 2
Participant flow — Part 2
MilestonePart 1: Tocilizumab (TCZ) Q2WPart 2: TCZ IV 12 mg/kg Q3W/Q4WPart 2: TCZ IV 8 mg/kg Q3W/Q4W
Started0715
Completed058
Not completed027
Withdrew: Adverse event001
Withdrew: Lack of efficacy011
Withdrew: Other001
Withdrew: Physician decision003
Withdrew: Protocol violation010
Withdrew: Withdrawal by subject001

Outcome measures

PrimaryJuvenile Arthritis Disease Activity Score (JADAS-71)

JADAS-71 has 4 components: Physician global assessment of disease activity on a visual analog scale (VAS) (range=0-10, left end of line=arthritis inactive, i.e., symptom-free and no arthritis symptoms; right end=arthritis very active), patient/parent global assessment of overall well-being on VAS (range=0-10, left end of line=very well, right end=very poor), normalized erythrocyte sedimentation rate (ESR) (range=0-10, If ESR is ≤20 mm/h, set to 0. If ≥120 mm/h, set to 10 mm/h. If \> 20 mm/h and \< 120 mm/h, apply formula: \[ESR-20 mm/h\]/10 mm/h), and a count of active arthritis (swelling present or pain present and limitation of motion) in 71 selected joints (range=0-71). JADAS-71 is sum of 4 component scores, range=0-101. A higher score=more arthritis disease activity. Data reported for up to Week 52 was collected in Part 2: Q3W arms: Baseline, Weeks 3,6,9,12,24,36,48 and 51; Q4W arms: Baseline, Weeks 0,4,8,12,24,36 and 40.

Time frame:
Part 2: Up to 52 weeks
Reported as:
Mean · score on a scale
Juvenile Arthritis Disease Activity Score (JADAS-71)
score on a scalePart 2: TCZ IV 12 mg/kg Q3WPart 2: TCZ IV 8 mg/kg Q3WPart 2: TCZ IV 12 mg/kg Q4WPart 2: TCZ IV 8 mg/kg Q4W
Baseline0.60 ± 0.8390.21 ± 0.2470.00 ± NA0.35 ± 0.295
Week 0——0.00 ± NA0.13 ± 0.242
Week 31.60 ± 2.4740.61 ± 0.913——
Week 4——0.00 ± NA0.17 ± 0.266
Week 60.54 ± 0.8120.39 ± 0.498——
Week 8——0.00 ± NA0.20 ± 0.490
Week 92.59 ± 5.4020.33 ± 0.420——
Week 120.30 ± 0.6000.84 ± 2.3180.00 ± NA0.13 ± 0.327
Week 240.42 ± 0.5760.05 ± 0.0840.00 ± NA0.20 ± 0.346
Week 360.48 ± 0.9500.08 ± 0.1500.00 ± NA0.00 ± 0.000
Week 40———0.00 ± 0.000
Week 480.00 ± 0.0000.17 ± 0.289——
Week 510.00 ± 0.0000.17 ± 0.208——
PrimaryNumber of Participants With Juvenile Idiopathic Arthritis (JIA) Disease Flare as Determined by JIA Core Variables in Part 2 of the Study

JIA flare was defined as any 3 of the 6 core outcome variables worsening by at least 30% relative to baseline visit of Part 2, with no more than 1 of the remaining variables improving by more than 30%. For the number of joints with active arthritis or the number of joints with limitation of motion a minimum worsening of at least 2 joints had to be present. If the physician global assessment (PGA) or the parent/patient global assessment were used a minimum worsening of at least 2 units on a scale from 0 to 10 had be present. For erythrocyte sedimentation rate (ESR), a worsening of at least 30% was not considered if within normal ranges. The 6 core outcome variables: PGA of disease activity, parent/patient global assessment of overall well-being, number of joints with active arthritis, number of joints with limitation of movement, ESR (measure of acute phase reaction) and functional ability determined by Childhood Health Assessment Questionnaire (CHAQ) Disability Index.

Time frame:
Part 2: Up to 52 weeks
Reported as:
Count of participants · Participants
Number of Participants With Juvenile Idiopathic Arthritis (JIA) Disease Flare as Determined by JIA Core Variables in Part 2 of the Study
ParticipantsPart 2: TCZ IV 12 mg/kg Q3WPart 2: TCZ IV 8 mg/kg Q3WPart 2: TCZ IV 12 mg/kg Q4WPart 2: TCZ IV 8 mg/kg Q4W
Number of Participants With Juvenile Idiopathic Arthritis (JIA) Disease Flare as Determined by JIA Core Variables in Part 2 of the Study1301
PrimaryNumber of Participants With Fever Attributable to Systemic Juvenile Idiopathic Arthritis (sJIA) in Part 2 of the Study

Absence of fever at screening visit was defined as a temperature measurement \< 38 degree centigrades (C). Presence of fever at each study visit was defined as a temperature measurement ≥ 38 C.

Time frame:
Part 2: Up to 52 weeks
Reported as:
Count of participants · Participants
Number of Participants With Fever Attributable to Systemic Juvenile Idiopathic Arthritis (sJIA) in Part 2 of the Study
ParticipantsPart 2: TCZ IV 12 mg/kg Q3WPart 2: TCZ IV 8 mg/kg Q3WPart 2: TCZ IV 12 mg/kg Q4WPart 2: TCZ IV 8 mg/kg Q4W
Number of Participants With Fever Attributable to Systemic Juvenile Idiopathic Arthritis (sJIA) in Part 2 of the Study0000
SecondaryNumber of Participants With at Least One Adverse Event

An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.

Time frame:
Part 1 - Baseline up to 24 weeks plus 12 weeks of safety follow up; Part 2 - Baseline up to 52 weeks plus 12 weeks of safety follow up
Reported as:
Count of participants · Participants
Number of Participants With at Least One Adverse Event
ParticipantsPart 1: Tocilizumab (TCZ) Q2WPart 2: TCZ IV 12 mg/kg Q3W/Q4WPart 2: TCZ IV 8 mg/kg Q3W/Q4W
Number of Participants With at Least One Adverse Event16714
SecondarySerum Interleukin-6 (IL-6) Protein Concentration in Part 2 of the Study
Time frame:
Part 2: Q3W arms: Pre-dose at Baseline, Weeks 3, 6, 9, 12, 24, 36, 48 and 51; Q4W arms: Pre-dose at Baseline, Weeks 0, 4, 8, 12, 24, 36 and 40
Reported as:
Mean · pg/mL
Serum Interleukin-6 (IL-6) Protein Concentration in Part 2 of the Study
pg/mLPart 2: TCZ IV 12 mg/kg Q3WPart 2: TCZ IV 8 mg/kg Q3WPart 2: TCZ IV 12 mg/kg Q4WPart 2: TCZ IV 8 mg/kg Q4W
Baseline36.340 ± 19.241323.453 ± 12.144051.500 ± NA25.415 ± 15.0174
Week 0———33.000 ± 23.3195
Week 361.617 ± 75.572422.727 ± 7.0321——
Week 4——13.700 ± NA28.364 ± 24.8937
Week 646.698 ± 50.714882.995 ± 216.2854——
Week 8——14.300 ± NA30.580 ± 22.0335
Week 945.231 ± 46.253947.582 ± 37.2259——
Week 1284.100 ± 57.897271.867 ± 156.471011.600 ± NA29.662 ± 26.0053
Week 2479.200 ± 44.885323.420 ± 14.552045.000 ± NA29.393 ± 19.2760
Week 3667.467 ± 84.731730.025 ± 16.547014.100 ± NA21.500 ± 15.8392
Week 40———22.820 ± 24.0133
Week 4814.533 ± 1.415415.400 ± 10.0936——
Week 5117.523 ± 9.20775.060 ± NA——
SecondarySoluble IL-6 Receptor (sIL-6R) Protein Concentration in Part 2 of the Study
Time frame:
Part 2: Q3W arms: Pre-dose at Baseline, Weeks 3, 6, 9, 12, 24, 36, 48 and 51; Q4W arms: Pre-dose at Baseline, Weeks 0, 4, 8, 12, 24, 36 and 40
Reported as:
Mean · ngEq/mL
Soluble IL-6 Receptor (sIL-6R) Protein Concentration in Part 2 of the Study
ngEq/mLPart 2: TCZ IV 12 mg/kg Q3WPart 2: TCZ IV 8 mg/kg Q3WPart 2: TCZ IV 12 mg/kg Q4WPart 2: TCZ IV 8 mg/kg Q4W
Baseline621.04 ± 443.779735.16 ± 310.983447.00 ± NA855.00 ± 325.572
Week 0——72.50 ± NA722.83 ± 229.530
Week 3632.43 ± 261.172707.73 ± 291.228——
Week 4——379.00 ± NA653.00 ± 143.386
Week 6518.67 ± 272.217721.73 ± 253.114——
Week 8——434.00 ± NA628.50 ± 145.891
Week 9596.58 ± 318.685646.92 ± 174.932——
Week 12656.80 ± 123.611666.75 ± 144.510411.00 ± NA645.33 ± 106.952
Week 24574.54 ± 347.127554.33 ± 124.498519.00 ± NA546.25 ± 330.265
Week 36492.50 ± 258.445646.00 ± 198.499439.00 ± NA599.75 ± 122.200
Week 40———609.50 ± 115.613
Week 48551.00 ± 91.000391.00 ± 220.293——
Week 51651.00 ± 135.765517.00 ± 140.007——
SecondaryC-reactive Protein (CRP) Concentration in Part 2 of the Study
Time frame:
Part 2: Q3W arms: Pre-dose at Baseline, Weeks 3, 6, 9, 12, 24, 36, 48 and 51; Q4W arms: Pre-dose at Baseline, Weeks 0, 4, 8, 12, 24, 36 and 40
Reported as:
Mean · mg/L
C-reactive Protein (CRP) Concentration in Part 2 of the Study
mg/LPart 2: TCZ IV 12 mg/kg Q3WPart 2: TCZ IV 8 mg/kg Q3WPart 2: TCZ IV 12 mg/kg Q4WPart 2: TCZ IV 8 mg/kg Q4W
Baseline4.844 ± 12.28322.309 ± 6.98470.200 ± NA0.958 ± 1.8575
Week 0——0.610 ± NA0.200 ± 0.0000
Week 30.223 ± 0.04270.216 ± 0.04070.200 ± NA0.200 ± 0.0000
Week 4——0.200 ± NA0.200 ± 0.0000
Week 60.291 ± 0.14990.526 ± 1.0163——
Week 8——0.200 ± NA0.200 ± 0.0000
Week 90.208 ± 0.01790.255 ± 0.12500.200 ± NA0.200 ± 0.0000
Week 120.200 ± 0.00000.238 ± 0.12010.200 ± NA0.203 ± 0.0082
Week 240.280 ± 0.17890.254 ± 0.12070.200 ± NA4.040 ± 8.5865
Week 360.225 ± 0.05000.200 ± 0.00000.200 ± NA0.200 ± 0.0000
Week 40———0.200 ± 0.0000
Week 480.200 ± 0.00000.820 ± 1.0739——
Week 510.318 ± 0.23500.200 ± 0.0000——
SecondaryErythrocyte Sedimentation Rate (ESR) in Part 2 of the Study
Time frame:
Part 2: Q3W arms: Pre-dose at Baseline, Weeks 3, 6, 9, 12, 24, 36, 48 and 51; Q4W arms: Pre-dose at Baseline, Weeks 0, 4, 8, 12, 24, 36 and 40
Reported as:
Mean · mm/h
Erythrocyte Sedimentation Rate (ESR) in Part 2 of the Study
mm/hPart 2: TCZ IV 12 mg/kg Q3WPart 2: TCZ IV 8 mg/kg Q3WPart 2: TCZ IV 12 mg/kg Q4WPart 2: TCZ IV 8 mg/kg Q4W
Baseline3.43 ± 5.1923.00 ± 1.8521.00 ± NA3.17 ± 1.602
Week 0——4.00 ± NA2.67 ± 1.633
Week 32.86 ± 2.0353.57 ± 2.7092.00 ± NA2.75 ± 0.957
Week 4——1.00 ± NA3.17 ± 1.722
Week 64.14 ± 4.5984.13 ± 3.681——
Week 8——1.00 ± NA3.33 ± 2.160
Week 92.50 ± 2.5103.23 ± 2.2043.00 ± NA2.25 ± 0.957
Week 122.20 ± 1.7893.92 ± 3.3151.00 ± NA4.50 ± 3.209
Week 242.80 ± 1.3043.17 ± 2.1371.00 ± NA2.80 ± 1.789
Week 362.25 ± 2.2174.50 ± 2.6461.00 ± NA2.25 ± 1.893
Week 40———2.25 ± 1.893
Week 483.00 ± 0.8164.67 ± 1.528——
Week 511.75 ± 1.7086.00 ± 3.000——
SecondaryNumber of Participants With Anti-TCZ Antibodies in Part 2 of the Study
Time frame:
Part 2: Up to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Anti-TCZ Antibodies in Part 2 of the Study
ParticipantsPart 2: TCZ IV 12 mg/kg Q3WPart 2: TCZ IV 8 mg/kg Q3WPart 2: TCZ IV 12 mg/kg Q4WPart 2: TCZ IV 8 mg/kg Q4W
Number of Participants With Anti-TCZ Antibodies in Part 2 of the Study0000
SecondarySerum TCZ Concentration in Part 2 of the Study
Time frame:
Part 2: Q3W arms: Pre-dose at Baseline, Weeks 3, 6, 9, 12, 24, 36, 48 and 51; Q4W arms: Pre-dose at Baseline, Weeks 0, 4, 8, 12, 24, 36 and 40
Reported as:
Mean · ug/mL
Serum TCZ Concentration in Part 2 of the Study
ug/mLPart 2: TCZ IV 12 mg/kg Q3WPart 2: TCZ IV 8 mg/kg Q3WPart 2: TCZ IV 12 mg/kg Q4WPart 2: TCZ IV 8 mg/kg Q4W
Baseline29.916 ± 35.800244.210 ± 33.25479.520 ± NA53.622 ± 48.5163
Week 0———24.212 ± 13.1659
Week 326.420 ± 21.184437.239 ± 21.8192——
Week 4——11.100 ± NA17.718 ± 11.1580
Week 628.636 ± 13.574430.482 ± 19.2402——
Week 8——22.800 ± NA17.578 ± 13.0611
Week 932.020 ± 6.373926.962 ± 17.9122——
Week 1237.600 ± 20.525444.763 ± 77.179823.800 ± NA15.442 ± 11.0714
Week 2424.363 ± 20.368620.842 ± 25.941730.300 ± NA16.030 ± 14.2124
Week 3630.517 ± 18.605819.733 ± 8.221819.800 ± NA12.903 ± 11.1808
Week 40———28.778 ± 16.0031
Week 4825.433 ± 34.305322.950 ± 0.9192——
Week 5112.207 ± 8.586210.945 ± 14.6449——
SecondaryBaseline Childhood Health Assessment Questionnaire (CHAQ) Disability Index in Part 2 of the Study

CHAQ- Disability Index consists of 30 questions in 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities-distributed, among a total of 30 items. Each question was rated on 4-point scale with range 0=no difficulty to 3=unable to do. To calculate overall score, participant must have a domain score in at least 6 of 8 domains. Scores were averaged to calculate CHAQ disability index, range is 0=no/minimal physical dysfunction)-3=very severe physical dysfunction, higher score indicates more disability.

Time frame:
Baseline of Part 2
Reported as:
Mean · score on a scale
Baseline Childhood Health Assessment Questionnaire (CHAQ) Disability Index in Part 2 of the Study
score on a scalePart 2: TCZ IV 12 mg/kg Q3WPart 2: TCZ IV 8 mg/kg Q3WPart 2: TCZ IV 12 mg/kg Q4WPart 2: TCZ IV 8 mg/kg Q4W
Baseline Childhood Health Assessment Questionnaire (CHAQ) Disability Index in Part 2 of the Study0.0000 ± 0.000000.0417 ± 0.090470.0000 ± NA0.0000 ± 0.00000
SecondaryChange From Baseline in Childhood Health Assessment Questionnaire (CHAQ) Disability Index in Part 2 of the Study

CHAQ- Disability Index consists of 30 questions in 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities-distributed, among a total of 30 items. Each question was rated on 4-point scale with range 0=no difficulty to 3=unable to do. To calculate overall score, participant must have a domain score in at least 6 of 8 domains. Scores were averaged to calculate CHAQ disability index, range is 0=no/minimal physical dysfunction)-3=very severe physical dysfunction, higher score indicates more disability. Negative change from baseline indicates an improvement.

Time frame:
Baseline; Part 2: Q3W arm groups - Weeks 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48 and 51; Q4W arm groups - Weeks 0, 4, 8, 12, 16, 20, 24, 28, 32, 36 and 40
Reported as:
Mean · score on a scale
Change From Baseline in Childhood Health Assessment Questionnaire (CHAQ) Disability Index in Part 2 of the Study
score on a scalePart 2: TCZ IV 12 mg/kg Q3WPart 2: TCZ IV 8 mg/kg Q3WPart 2: TCZ IV 12 mg/kg Q4WPart 2: TCZ IV 8 mg/kg Q4W
Change from Baseline at Week 0——0.0000 ± NA0.0000 ± 0.00000
Change from Baseline at Week 30.2500 ± 0.661440.0167 ± 0.25384——
Change from Baseline at Week 4——0.0000 ± NA0.0000 ± 0.00000
Change from Baseline at Week 60.1071 ± 0.28347-0.0083 ± 0.07420——
Change from Baseline at Week 8——0.0000 ± NA0.0000 ± 0.00000
Change from Baseline at Week 90.2500 ± 0.51539-0.0268 ± 0.10022——
Change from Baseline at Week 120.1250 ± 0.27951-0.0481 ± 0.095990.0000 ± NA0.0000 ± 0.00000
Change from Baseline at Week 150.1458 ± 0.357220.1771 ± 0.54994——
Change from Baseline at Week 16——0.0000 ± NA0.0000 ± 0.00000
Change from Baseline at Week 180.1000 ± 0.223610.2500 ± 0.85009——
Change from Baseline at Week 20——0.0000 ± NA0.0000 ± 0.00000
Change from Baseline at Week 210.0000 ± 0.000000.2656 ± 0.90740——
Change from Baseline at Week 240.1250 ± 0.27951-0.0750 ± 0.111800.0000 ± NA0.0000 ± 0.00000
Change from Baseline at Week 270.0000 ± 0.000000.0000 ± 0.10206——
Change from Baseline at Week 28——0.0000 ± NA0.0000 ± 0.00000
Change from Baseline at Week 300.0000 ± 0.000000.0000 ± 0.00000——
Change from Baseline at Week 32——0.0000 ± NA0.0000 ± 0.00000
Change from Baseline at Week 330.0000 ± 0.00000-0.0417 ± 0.07217——
Change from Baseline at Week 360.0000 ± 0.000000.0417 ± 0.072170.0000 ± NA0.0000 ± 0.00000
Change from Baseline at Week 390.0000 ± 0.00000-0.0417 ± 0.07217——
Change from Baseline at Week 40———0.0000 ± 0.00000
Change from Baseline at Week 420.0000 ± 0.00000-0.0417 ± 0.07217——
Change from Baseline at Week 450.0000 ± 0.00000-0.0417 ± 0.07217——
Change from Baseline at Week 480.0000 ± 0.00000-0.0417 ± 0.07217——
Change from Baseline at Week 510.0000 ± 0.00000-0.0417 ± 0.07217——
SecondaryBaseline Participant's/Parent's Global Assessment of Overall Well-being Score in Part 2 of the Study

Participant's/parent's global assessment of overall well-being was determined on a VAS (range = 0-100, left end of the line = very well, i.e., symptom-free and no arthritis disease activity; right end = very poor, i.e., maximum arthritis disease activity).

Time frame:
Baseline of Part 2
Reported as:
Mean · score on a scale
Baseline Participant's/Parent's Global Assessment of Overall Well-being Score in Part 2 of the Study
score on a scalePart 2: TCZ IV 12 mg/kg Q3WPart 2: TCZ IV 8 mg/kg Q3WPart 2: TCZ IV 12 mg/kg Q4WPart 2: TCZ IV 8 mg/kg Q4W
Baseline Participant's/Parent's Global Assessment of Overall Well-being Score in Part 2 of the Study2.3 ± 3.951.6 ± 2.290.0 ± NA2.5 ± 3.21
SecondaryChange From Baseline in Participant's/Parent's Global Assessment of Overall Well-being Score in Part 2 of the Study

Participant's/Parent's global assessment of overall well-being was determined on a VAS (range = 0-100, left end of the line = very well, i.e., symptom-free and no arthritis disease activity; right end = very poor, i.e., maximum arthritis disease activity). Reported is the change from baseline in VAS score with a negative change from baseline indicating an improvement.

Time frame:
Baseline; Part 2: Q3W arm groups - Weeks 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48 and 51; Q4W arm groups - Weeks 0, 4, 8, 12, 16, 20, 24, 28, 32, 36 and 40
Reported as:
Mean · score on a scale
Change From Baseline in Participant's/Parent's Global Assessment of Overall Well-being Score in Part 2 of the Study
score on a scalePart 2: TCZ IV 12 mg/kg Q3WPart 2: TCZ IV 8 mg/kg Q3WPart 2: TCZ IV 12 mg/kg Q4WPart 2: TCZ IV 8 mg/kg Q4W
Change from Baseline at Week 0——0.0000 ± NA-1.2 ± 1.60
Change from Baseline at Week 3-0.3 ± 2.362.0 ± 6.12——
Change from Baseline at Week 4——0.0000 ± NA-1.2 ± 1.26
Change from Baseline at Week 6-1.6 ± 3.512.2 ± 4.55——
Change from Baseline at Week 8——0.0 ± NA-0.5 ± 3.56
Change from Baseline at Week 98.4 ± 26.480.1 ± 2.62——
Change from Baseline at Week 12-1.6 ± 3.58-0.7 ± 2.320.0 ± NA-1.2 ± 2.56
Change from Baseline at Week 15-1.5 ± 3.677.1 ± 29.34——
Change from Baseline at Week 16——0.0 ± NA-1.5 ± 1.97
Change from Baseline at Week 18-1.4 ± 3.716.9 ± 23.26——
Change from Baseline at Week 20——0.0 ± NA-1.6 ± 2.61
Change from Baseline at Week 210.0 ± 0.009.9 ± 30.02——
Change from Baseline at Week 24-1.8 ± 4.02-0.8 ± 2.170.0 ± NA-1.0 ± 2.00
Change from Baseline at Week 270.0 ± 0.000.3 ± 2.87——
Change from Baseline at Week 28——0.0 ± NA-1.2 ± 2.39
Change from Baseline at Week 300.0 ± 0.00-0.3 ± 2.52——
Change from Baseline at Week 32——0.0 ± NA5.4 ± 14.35
Change from Baseline at Week 3325.0 ± 50.000.0 ± 3.00——
Change from Baseline at Week 360.3 ± 0.500.0 ± 3.000.0 ± NA-2.0 ± 2.83
Change from Baseline at Week 390.3 ± 0.50-1.0 ± 1.73——
Change from Baseline at Week 40———-2.7 ± 3.06
Change from Baseline at Week 420.0 ± 0.00-0.7 ± 2.08——
Change from Baseline at Week 450.0 ± 0.000.3 ± 3.51——
Change from Baseline at Week 480.0 ± 0.000.7 ± 4.04——
Change from Baseline at Week 510.0 ± 0.000.3 ± 3.51——

Adverse events

Collected over Part 1 - Up to 24 weeks plus 12 weeks safety follow up; Part 2 - Up to 52 weeks plus 12 weeks safety follow up. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Tocilizumab (TCZ) Q2W0/19 (0%)1/19 (5.3%)16/19 (84.2%)
Part 2: TCZ IV 12 mg/kg Q3W/Q4W0/7 (0%)1/7 (14.3%)7/7 (100%)
Part 2: TCZ IV 8 mg/kg Q3W/Q4W0/15 (0%)1/15 (6.7%)14/15 (93.3%)
Most frequent serious events
Most frequent serious events
EventPart 1: Tocilizumab (TCZ) Q2WPart 2: TCZ IV 12 mg/kg Q3W/Q4WPart 2: TCZ IV 8 mg/kg Q3W/Q4W
PNEUMONIAInfections and infestations0/191/70/15
HYPERTRANSAMINASAEMIAHepatobiliary disorders0/190/71/15
HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSISImmune system disorders1/190/70/15
Most frequent other events
Showing 10 of 89
Most frequent other events
EventPart 1: Tocilizumab (TCZ) Q2WPart 2: TCZ IV 12 mg/kg Q3W/Q4WPart 2: TCZ IV 8 mg/kg Q3W/Q4W
PHARYNGITISInfections and infestations0/192/70/15
URINARY TRACT INFECTIONInfections and infestations2/192/72/15
ARTHROPOD BITEInjury, poisoning and procedural complications3/192/70/15
RASHSkin and subcutaneous tissue disorders3/192/70/15
LEUKOPENIABlood and lymphatic system disorders0/190/73/15
NEUTROPENIABlood and lymphatic system disorders1/191/73/15
NASOPHARYNGITISInfections and infestations1/191/73/15
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations3/190/73/15
EAR PAINEar and labyrinth disorders0/191/70/15
EAR SWELLINGEar and labyrinth disorders0/191/70/15

Baseline characteristics

Part 1 enrolled 19. Patients treated with TCZ Q2W either during Part 1 or prior to the study, who experienced laboratory abnormalities and which had resolved, were allowed to enroll into Part 2. Part 2 enrolled 22 with 6 from Part 1 and 16 directly enrolled into Part 2. Baseline Characteristics are presented separately for Part 1 and Part 2.

Age, Continuous
Age, Continuous(years)Part 1: Tocilizumab (TCZ) Q2WPart 2: TCZ IV 12 mg/kg Q3W/Q4WPart 2: TCZ IV 8 mg/kg Q3W/Q4WTotal
Mean8.5 ± 3.6——8.5 ± 3.6
Age, Continuous
Age, Continuous(years)Part 1: Tocilizumab (TCZ) Q2WPart 2: TCZ IV 12 mg/kg Q3W/Q4WPart 2: TCZ IV 8 mg/kg Q3W/Q4WTotal
Mean—6.7 ± 1.811.7 ± 2.810.1 ± 3.4
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: Tocilizumab (TCZ) Q2WPart 2: TCZ IV 12 mg/kg Q3W/Q4WPart 2: TCZ IV 8 mg/kg Q3W/Q4WTotal
Female9009
Male100010
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: Tocilizumab (TCZ) Q2WPart 2: TCZ IV 12 mg/kg Q3W/Q4WPart 2: TCZ IV 8 mg/kg Q3W/Q4WTotal
Female041014
Male0358
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1: Tocilizumab (TCZ) Q2WPart 2: TCZ IV 12 mg/kg Q3W/Q4WPart 2: TCZ IV 8 mg/kg Q3W/Q4WTotal
Hispanic or Latino6006
Not Hispanic or Latino130013
Unknown or Not Reported0000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1: Tocilizumab (TCZ) Q2WPart 2: TCZ IV 12 mg/kg Q3W/Q4WPart 2: TCZ IV 8 mg/kg Q3W/Q4WTotal
Hispanic or Latino0246
Not Hispanic or Latino051015
Unknown or Not Reported0011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1: Tocilizumab (TCZ) Q2WPart 2: TCZ IV 12 mg/kg Q3W/Q4WPart 2: TCZ IV 8 mg/kg Q3W/Q4WTotal
American Indian or Alaska Native1001
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White170017
More than one race0000
Unknown or Not Reported1001
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1: Tocilizumab (TCZ) Q2WPart 2: TCZ IV 12 mg/kg Q3W/Q4WPart 2: TCZ IV 8 mg/kg Q3W/Q4WTotal
American Indian or Alaska Native0123
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White061218
More than one race0000
Unknown or Not Reported0011
08

Study locations

19 sites
  • Children's Hospital Los Angeles; Division of Rheumatoogy
    Los Angeles, California 90027, United States
  • Cincinnati Children'S Hospital Medical Center; Division of Rheumatology
    Cincinnati, Ohio 45229-3039, United States
  • Hospital Gral de Niños Pedro Elizalde
    Buenos Aires, 1270, Argentina
  • Hospital Dr. Humberto Notti
    Mendoza, 5519, Argentina
  • Alberta Children'S Hospital
    Calgary, Alberta T3B 6A8, Canada
  • Charité Campus; Virchow Klinikum Berlin
    Berlin, 13353, Germany
  • Asklepios Klinik; Zentrum für Allgemeine Pädiatrie und Neonatologie
    Sankt Augustin, 53757, Germany
  • Rambam Medicl Center, Ruth Children Hospital
    Haifa, 3109601, Israel
  • Meir Medical center, Pediatrics
    Kfar Sava, 4428164, Israel
  • Schneider Children's Medical Center of Israel
    Petach Tikva, 4920235, Israel
  • Irccs Ospedale Pediatrico Bambin Gesu - Dip. Di Medicina
    Roma, Lazio 00165, Italy
  • Univ. Di Padova - Dip. Di Pediatria - Unita' Reumatol. Pediatrica
    Padova, Veneto 35128, Italy
  • Unidad de Reumatologia Rehabilitacion Integral; Centro Medico Del Angel
    Mexicali, 21100, Mexico
  • SI Sceintific children health center RAMS
    Moscow, 119991, Russian Federation
  • Saint-Petersburg State; Pediatrics Medical Academy
    Saint-Petersburg, 194100, Russian Federation
  • Hospital Sant Joan De Deu; Servicio de Reumatologia Pediatrica
    Barcelona, 08950, Spain
  • Hospital Ramon y Cajal ; Servicio de Reumatologia
    Madrid, 28034, Spain
  • Hospital de La Paz; Unidad de Reumatologia Pediatrica
    Madrid, 28046, Spain
  • Royal Liverpool Childrens Hospital; Rheumatology
    Liverpool, L12 2AP, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2013 to primary completion in Oct 2019, 75 months.

Results were first posted in Apr 2020, 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2012
First posted
Nov 27, 2012
StartActual
Jun 10, 2013
Primary completionActual
Oct 9, 2019
CompletionActual
Oct 9, 2019
Results first posted
Apr 24, 2020
Last update
Apr 24, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01734382
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Nov 27, 2012
Start date
Jun 10, 2013
Primary completion
Oct 9, 2019
Completion
Oct 9, 2019
Results posted
Apr 24, 2020
Last update
Apr 24, 2020

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tocilizumab

Start the discussion